PARP inhibitors as maintenance treatment for pancreatic cancer patients with germline BRCA mutations

被引：0
作者：
Kawecki, Maciej [1 ]
机构：
[1] Maria Sklodowska Curie Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2019年 / 15卷 / 03期
关键词：
D O I：
10.5603/OCP.2019.0023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：190 / 193
页数：4
相关论文
共 6 条
  • [1] Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.
    Bell, Erica Hlavin
    Won, Minhee
    Fleming, Jessica L.
    Becker, Aline P.
    McElroy, Joseph P.
    Shaw, Edward G.
    Mehta, Minesh P.
    Brachman, David G.
    Gertler, Stanley Z.
    Murtha, Albert D.
    Schultz, Christopher J.
    Johnson, David B.
    Laack, Nadia N.
    Hunter, Grant Kirton
    Crocker, Ian R.
    Chakravarti, Arnab
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
    Buckner, Jan C.
    Shaw, Edward G.
    Pugh, Stephanie L.
    Chakravarti, Arnab
    Gilbert, Mark R.
    Barger, Geoffrey R.
    Coons, Stephen
    Ricci, Peter
    Bullard, Dennis
    Brown, Paul D.
    Stelzer, Keith
    Brachman, David
    Suh, John H.
    Schultz, Christopher J.
    Bahary, Jean-Paul
    Fisher, Barbara J.
    Kim, Harold
    Murtha, Albert D.
    Bell, Erica H.
    Won, Minhee
    Mehta, Minesh P.
    Curran, Walter J., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (14) : 1344 - 1355
  • [3] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Conroy, Thierry
    Desseigne, Francoise
    Ychou, Marc
    Bouche, Olivier
    Guimbaud, Rosine
    Becouarn, Yves
    Adenis, Antoine
    Raoul, Jean-Luc
    Gourgou-Bourgade, Sophie
    de la Fouchardiere, Christelle
    Bennouna, Jaafar
    Bachet, Jean-Baptiste
    Khemissa-Akouz, Faiza
    Pere-Verge, Denis
    Delbaldo, Catherine
    Assenat, Eric
    Chauffert, Bruno
    Michel, Pierre
    Montoto-Grillot, Christine
    Ducreux, Michel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) : 1817 - 1825
  • [4] FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).
    Dahan, Laetitia
    Phelip, Jean Marc
    Le Malicot, Karine
    Williet, Nicolas
    Desrame, Jerome
    Volet, Julien
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
    Golan, Talia
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Park, Joon-Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke
    Tortora, Giampaolo
    Alguel, Hana
    O'Reilly, Eileen M.
    McGuinness, David
    Cui, Karen Y.
    Schlienger, Katia
    Locker, Gershon Y.
    Kindler, Hedy L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04) : 317 - 327
  • [6] Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.
    Hall, Peter S.
    Swinson, Daniel
    Waters, Justin S.
    Wadsley, Jonathan
    Falk, Stephen
    Roy, Rajarshi
    Tillett, Tania
    Nicoll, Jonathan
    Cummings, Sebastian
    Grumett, Simon Aird
    Kamposioras, Konstantinos
    Garcia, Angel
    Allmark, Christine
    Marshall, Helen
    Ruddock, Sharon
    Katona, Eszter
    Velikova, Galina
    Petty, Russell D.
    Grabsch, Heike I.
    Seymour, Matthew T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
1